Live Breaking News & Updates on Second Line Therapies

Stay updated with breaking news from Second line therapies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

The Evolving Landscape of Second-Line Therapies in HCC Management

The Evolving Landscape of Second-Line Therapies in HCC Management
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Tyrosine Kinase Inhibitors , Unresectable Hepatocellular Carcinoma , Evolving Landscape , Second Line Therapies ,

Multiple Myeloma Market to Observe Impressive Growth at a CAGR of ~5% During the Study Period (2019-2032), Assesses DelveInsight

/PRNewswire/ DelveInsight s Multiple Myeloma Market Insights report includes a comprehensive understanding of current treatment practices, multiple myeloma. ....

United States , United Kingdom , Zevorcabtagene Autoleucel , Prnewswire Delveinsight , Johnson Janssen , Bristol Myers Squibb Celgene , Heidelberg Pharma , Orvacabtagene Autoleucel , Abbvie Teneoone , Ascentage Pharma , Shruti Thakur , Roche Genentech , Bristol Myers Squibb , Novartis Incyte Corporation , Janssen Research Development , Delveinsight Business Research , Market Research , Key Companies , Nerviano Medical Sciences , Key Multiple Myeloma Companies , Regeneron Pharmaceuticals , Ionis Pharmaceuticals , Myeloma Market Insights , Multiple Myeloma Market , Cartesian Therapeutics , Cell Therapy ,

HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway

Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development. ....

Aditya Bardia , Gregory Vidal , Komal Jhaveri , Hr Her2 Breast Cancer , Cdk4 6 Inhibitors , Second Line Therapies , Endocrine Therapy , Endocrine Resistance , Akt Inhibitors , Capitello 291 , Maintain Trial , Ember 3 , Oral Serds , Viktoria 1 ,

Potential Approaches to Treatment Switching in HR+/HER2- mBC

Experts share how they approach management of patients with disease progression on first-line endocrine therapy, with a focus on ESR1 mutation testing and identifying who might be suitable for treatment with the oral SERD elacestrant. ....

Komal Jhaveri , Timothy Pluard , Aditya Bardia , Hr Her2 Breast Cancer , Cdk4 6 Inhibitors , Second Line Therapies , Endocrine Therapy , Emerald Trial ,

HMP Global Announces Distinguished Faculty Lineup for Inaugural Great Debates & Updates in Women's Oncology

HMP Global Announces Distinguished Faculty Lineup for Inaugural Great Debates & Updates in Women’s Oncology
Share Article
Program features clinical insight from prominent experts in the fields of gynecological and breast cancers; two-day agenda will address hot topics in an interactive, engaging format
“Delivered in the highly popular and uniquely interactive Great Debates & Updates format, this program will offer participants an engaging, educational opportunity,” said Kathleen N. Moore, MD, MS, and Conference Co-Chair of GDU Women’s Oncology.
MALVERN, Pa. (PRWEB)
April 14, 2021
HMP Global, a leading healthcare event and education company, today announced the agenda and faculty lineup for its inaugural Great Debates & Updates in Women’s Oncology, taking place online April 23-24 via the company’s VRTX virtual events platform. The meeting’s faculty is comprised of a distinguishe ....

United States , San Francisco , Nikhil Wagle , Carey Anders , Kathleenn Moore , Heatherl Mcarthur , Duke Cancer Institute , Conference Co , University Of California , Gynecologic Cancer Program , Sinai Medical Center , Psych Congress , Harvard Medical School , Stephenson Cancer Center , Sarah Cannon Research Institute Tennessee Oncology , Clinical Research , Dana Farber Cancer Institute , Helen Diller Family Comprehensive Cancer Center , Great Debates , Conference Co Chair , Sarah Cannon Research , Tennessee Oncology , Breast Cancer , Virginia Kerley Cade Endowed Chair , Developmental Therapeutics , Associate Director ,